{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:34:45Z","timestamp":1789004085459,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Healthcare Business of Merck KGaA","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13242-5","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:25:18Z","timestamp":1775924718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antimalarial cabamiquine inhibits blood-stage of different field isolates of Plasmodium species"],"prefix":"10.1186","volume":"26","author":[{"given":"Laurent","family":"Dembele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw","family":"Aniweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alamissa","family":"Soulama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanta","family":"Sogore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ousmaila","family":"Diakit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas N.","family":"Amenga-Etego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Demarta-Gatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye A.","family":"Djimde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"13242_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpara.2021.06.003","volume":"52","author":"MA Abdulraheem","year":"2022","unstructured":"Abdulraheem MA, et al. High prevalence of Plasmodium malariae and Plasmodium ovale in co-infections with Plasmodium falciparum in asymptomatic malaria parasite carriers in southwestern Nigeria. Int J Parasitol. 2022;52(1):23\u201333.","journal-title":"Int J Parasitol"},{"issue":"10","key":"13242_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jmoldx.2021.07.022","volume":"23","author":"F Ansah","year":"2021","unstructured":"Ansah F, et al. Development of Cooperative Primer-Based Real-Time PCR Assays for the Detection of Plasmodium malariae and Plasmodium ovale. J Mol Diagn. 2021;23(10):1393\u2013403.","journal-title":"J Mol Diagn"},{"issue":"3","key":"13242_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/CMR.18.3.570-581.2005","volume":"18","author":"WE Collins","year":"2005","unstructured":"Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev. 2005;18(3):570\u201381.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"13242_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12879-023-08381-y","volume":"23","author":"L Dembele","year":"2023","unstructured":"Dembele L, et al. Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs. BMC Infect Dis. 2023;23(1):405.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"13242_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/infdis\/jix686","volume":"217","author":"M Betson","year":"2018","unstructured":"Betson M, et al. Emergence of Nonfalciparum Plasmodium Infection Despite Regular Artemisinin Combination Therapy in an 18-Month Longitudinal Study of Ugandan Children and Their Mothers. J Infect Dis. 2018;217(7):1099\u2013109.","journal-title":"J Infect Dis"},{"key":"13242_CR6","doi-asserted-by":"crossref","unstructured":"Douglas NM, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med. 2013; 10(12): p. e1001575. discussion e1001575.","DOI":"10.1371\/journal.pmed.1001575"},{"issue":"1","key":"13242_CR7","doi-asserted-by":"publisher","first-page":"ofu034","DOI":"10.1093\/ofid\/ofu034","volume":"1","author":"J Hwang","year":"2014","unstructured":"Hwang J, et al. Severe morbidity and mortality risk from malaria in the United States, 1985\u20132011. Open Forum Infect Dis. 2014;1(1):ofu034.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"13242_CR8","doi-asserted-by":"publisher","first-page":"e0004195","DOI":"10.1371\/journal.pntd.0004195","volume":"9","author":"S Langford","year":"2015","unstructured":"Langford S, et al. Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Negl Trop Dis. 2015;9(12):e0004195.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"13242_CR9","doi-asserted-by":"publisher","first-page":"e0007414","DOI":"10.1371\/journal.pntd.0007414","volume":"13","author":"V Yman","year":"2019","unstructured":"Yman V, et al. Persistent transmission of Plasmodium malariae and Plasmodium ovale species in an area of declining Plasmodium falciparum transmission in eastern Tanzania. PLoS Negl Trop Dis. 2019;13(5):e0007414.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"13242_CR10","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00436-016-5043-0","volume":"115","author":"J Richter","year":"2016","unstructured":"Richter J, et al. Clinical implications of a gradual dormancy concept in malaria. Parasitol Res. 2016;115(6):2139\u201348.","journal-title":"Parasitol Res"},{"issue":"10","key":"13242_CR11","doi-asserted-by":"publisher","first-page":"e1001891","DOI":"10.1371\/journal.pmed.1001891","volume":"12","author":"LJ Robinson","year":"2015","unstructured":"Robinson LJ, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015;12(10):e1001891.","journal-title":"PLoS Med"},{"issue":"3","key":"13242_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1365-3156.2002.00857.x","volume":"7","author":"TT Win","year":"2002","unstructured":"Win TT, et al. Wide distribution of Plasmodium ovale in Myanmar. Trop Med Int Health. 2002;7(3):231\u20139.","journal-title":"Trop Med Int Health"},{"issue":"3","key":"13242_CR13","doi-asserted-by":"publisher","first-page":"e0491622","DOI":"10.1128\/spectrum.04916-22","volume":"11","author":"Y Aniweh","year":"2023","unstructured":"Aniweh Y, et al. Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana. Microbiol Spectr. 2023;11(3):e0491622.","journal-title":"Microbiol Spectr"},{"issue":"8","key":"13242_CR14","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/jac\/dkab133","volume":"76","author":"L Dembele","year":"2021","unstructured":"Dembele L, et al. Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali. J Antimicrob Chemother. 2021;76(8):2079\u201387.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"13242_CR15","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1021\/acsinfecdis.1c00262","volume":"7","author":"L Dembele","year":"2021","unstructured":"Dembele L, et al. Ex Vivo Plasmodium malariae Culture Method for Antimalarial Drugs Screen in the Field. ACS Infect Dis. 2021;7(11):3025\u201333.","journal-title":"ACS Infect Dis"},{"issue":"6","key":"13242_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ijpara.2011.01.004","volume":"41","author":"MC Oguike","year":"2011","unstructured":"Oguike MC, et al. Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. Int J Parasitol. 2011;41(6):677\u201383.","journal-title":"Int J Parasitol"},{"issue":"10128","key":"13242_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"West African Network for Clinical Trials of Antimalarial","year":"2018","unstructured":"West African Network for Clinical Trials of Antimalarial. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet. 2018;391(10128):1378\u201390.","journal-title":"Lancet"},{"key":"13242_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijpddr.2013.01.001","volume":"3","author":"B Dinko","year":"2013","unstructured":"Dinko B, et al. Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian school-children. Int J Parasitol Drugs Drug Resist. 2013;3:45\u201350.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1","key":"13242_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12936-018-2480-5","volume":"17","author":"H Kavunga-Membo","year":"2018","unstructured":"Kavunga-Membo H, et al. Molecular identification of Plasmodium species in symptomatic children of Democratic Republic of Congo. Malar J. 2018;17(1):334.","journal-title":"Malar J"},{"issue":"3","key":"13242_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019;380(3):215\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"13242_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/jiaa478","volume":"223","author":"CL Mitchell","year":"2021","unstructured":"Mitchell CL, et al. Under the Radar: Epidemiology of Plasmodium ovale in the Democratic Republic of the Congo. J Infect Dis. 2021;223(6):1005\u201314.","journal-title":"J Infect Dis"},{"key":"13242_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1475-2875-12-113","volume":"12","author":"P Obare","year":"2013","unstructured":"Obare P, et al. Misclassification of Plasmodium infections by conventional microscopy and the impact of remedial training on the proficiency of laboratory technicians in species identification. Malar J. 2013;12:113.","journal-title":"Malar J"},{"issue":"6","key":"13242_CR23","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.4269\/ajtmh.20-0593","volume":"103","author":"EC Oriero","year":"2020","unstructured":"Oriero EC, et al. Seroprevalence and Parasite Rates of Plasmodium malariae in a High Malaria Transmission Setting of Southern Nigeria. Am J Trop Med Hyg. 2020;103(6):2208\u201316.","journal-title":"Am J Trop Med Hyg"},{"issue":"7556","key":"13242_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baragana","year":"2015","unstructured":"Baragana B, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522(7556):315\u201320.","journal-title":"Nature"},{"issue":"8","key":"13242_CR25","doi-asserted-by":"publisher","first-page":"e2389","DOI":"10.1002\/bdr2.2389","volume":"116","author":"A Gado","year":"2024","unstructured":"Gado A, et al. Absence of developmental and reproductive toxicity in rats, rabbits, and zebrafish embryos exposed to antimalarial drug cabamiquine. Birth Defects Res. 2024;116(8):e2389.","journal-title":"Birth Defects Res"},{"issue":"12","key":"13242_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"JS McCarthy","year":"2021","unstructured":"McCarthy JS, et al. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Lancet Infect Dis. 2021;21(12):1713\u201324.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"13242_CR27","doi-asserted-by":"publisher","first-page":"e0079324","DOI":"10.1128\/aac.00793-24","volume":"68","author":"JL McLellan","year":"2024","unstructured":"McLellan JL, et al. A high content imaging assay for identification of specific inhibitors of native Plasmodium liver stage protein synthesis. Antimicrob Agents Chemother. 2024;68(10):e0079324.","journal-title":"Antimicrob Agents Chemother"},{"key":"13242_CR28","doi-asserted-by":"crossref","unstructured":"Rottmann M et al. Preclinical antimalarial combination study of M5717, a plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor. Antimicrob Agents Chemother. 2020;64(4).","DOI":"10.1128\/AAC.02181-19"},{"issue":"12","key":"13242_CR29","doi-asserted-by":"publisher","first-page":"e0089123","DOI":"10.1128\/aac.00891-23","volume":"67","author":"P Courlet","year":"2023","unstructured":"Courlet P, et al. Semi-mechanistic population pharmacokinetic\/pharmacodynamic modeling of a Plasmodium elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria. Antimicrob Agents Chemother. 2023;67(12):e0089123.","journal-title":"Antimicrob Agents Chemother"},{"key":"13242_CR30","doi-asserted-by":"publisher","first-page":"116006","DOI":"10.1016\/j.taap.2022.116006","volume":"443","author":"P Hewitt","year":"2022","unstructured":"Hewitt P, et al. An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2. Toxicol Appl Pharmacol. 2022;443:116006.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"13242_CR31","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1038\/s41467-023-40974-8","volume":"14","author":"E Stadler","year":"2023","unstructured":"Stadler E, et al. Propensity of selecting mutant parasites for the antimalarial drug cabamiquine. Nat Commun. 2023;14(1):5205.","journal-title":"Nat Commun"},{"key":"13242_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1475-2875-13-207","volume":"13","author":"H Tinto","year":"2014","unstructured":"Tinto H, et al. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malar J. 2014;13:207.","journal-title":"Malar J"},{"key":"13242_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijpddr.2021.07.002","volume":"17","author":"DA van Schalkwyk","year":"2021","unstructured":"van Schalkwyk DA, et al. Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species. Int J Parasitol Drugs Drug Resist. 2021;17:5\u201311.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1","key":"13242_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12936-023-04482-w","volume":"22","author":"SY Ahorhorlu","year":"2023","unstructured":"Ahorhorlu SY, et al. Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana. Malar J. 2023;22(1):58.","journal-title":"Malar J"},{"issue":"1","key":"13242_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13071-022-05153-6","volume":"15","author":"LE Amoah","year":"2022","unstructured":"Amoah LE, et al. Nationwide molecular surveillance of three Plasmodium species harboured by symptomatic malaria patients living in Ghana. Parasit Vectors. 2022;15(1):40.","journal-title":"Parasit Vectors"},{"issue":"2","key":"13242_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","volume":"16","author":"I Sagara","year":"2016","unstructured":"Sagara I, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16(2):189\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"13242_CR37","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1128\/AAC.41.10.2317","volume":"41","author":"P Ringwald","year":"1997","unstructured":"Ringwald P, et al. Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob Agents Chemother. 1997;41(10):2317\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"13242_CR38","doi-asserted-by":"publisher","unstructured":"Adika E, et al. Plasmodium falciparum isolates: ex vivo drug response. J Antimicrob Chemother. 2025;80(7):1813\u201322. https:\/\/doi.org\/10.1093\/jac\/dkaf129.","DOI":"10.1093\/jac\/dkaf129"},{"issue":"1","key":"13242_CR39","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1186\/s12889-019-7989-1","volume":"19","author":"LE Amoah","year":"2019","unstructured":"Amoah LE, et al. Probing the composition of Plasmodium species contained in malaria infections in the Eastern region of Ghana. BMC Public Health. 2019;19(1):1617.","journal-title":"BMC Public Health"},{"issue":"7","key":"13242_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ijpara.2007.12.002","volume":"38","author":"H Kaddouri","year":"2008","unstructured":"Kaddouri H, et al. Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int J Parasitol. 2008;38(7):791\u20138.","journal-title":"Int J Parasitol"},{"issue":"1","key":"13242_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4269\/ajtmh.2002.67.39","volume":"67","author":"M Ramharter","year":"2002","unstructured":"Ramharter M, et al. In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum. Am J Trop Med Hyg. 2002;67(1):39\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"13242_CR42","doi-asserted-by":"crossref","unstructured":"Mbye H, et al. Tolerance of gambian plasmodium falciparum to dihydroartemisinin and lumefantrine detected by ex vivo parasite survival rate assay. Antimicrob Agents Chemother. 2020;65(1).","DOI":"10.1128\/AAC.00720-20"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13242-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:14:13Z","timestamp":1779408853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13242-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13242"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13242-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6972717\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Ghana Health Service Ethical Review Committee of Ghana with the reference GHS-ERC (GHSERC005\/12\/17) and the ethical committee of the Faculties of Medicine-Odonto-Stomatology and Pharmacy, University of Science, Techniques and Technologies of Bamako, Mali with the references N\u00b02022\/03\/CE\/ USTTB, and N\u00b02023\/03\/CE\/USTTB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed and approved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"997"}}